IntelliChem Names Dr. David Pearson to Board of Directors
IntelliChem, Inc, the leading provider of intelligent electronic lab notebooks (iELN) for discovery and development, today announced that David Pearson, Ph.D., has joined the company’s board of directors.
In a career that has spanned 20 years, Dr. Pearson has held numerous senior management positions within Sandoz Pharma and Novartis Pharma, before joining Noxxon Pharma AG as chief executive officer. He worked at Sandoz headquarters as Strategic Business Unit Head, leading global product launches for some of Sandoz’s largest products, including LamisilTM. While at Novartis, Dr. Pearson ran the Cardiovascular Business Unit in Switzerland before becoming the General Manager for Novartis in the Czech Republic.
In addition to these traditional management roles, Dr. Pearson was also chosen to advise Novartis senior management on the implementation of e-Business. This led to his appointment as the Director of e-Business for Novartis UK, where he built the first internet-based system selling directly to physicians, while building a reputation as a technology innovator.
Dr. Pearson is presently Senior Vice President at SkinMedica, a California-based specialty pharmaceuticals company developing and commercializing dermatology products. A graduate of Rice University in Biochemistry and French, Dr. Pearson earned his MBA at the Sloan School of Management at MIT and his Ph.D. from Yale University in Molecular Biophysics and Biochemistry.
“I am delighted to welcome Dr. David Pearson to the IntelliChem board,” said Dr. Paul van Eikeren, President & CEO of IntelliChem. “His knowledge and understanding of the tactical and strategic issues facing the global pharmaceutical industry will help IntelliChem define optimal strategies to best serve the needs of the pharmaceutical industry as we strive to create the iELN as an industry standard. We look forward to David’s contributions as an active board member.”
“The successful adoption of electronic lab notebooks is critical as pharmaceutical and biotechnology companies must strive to dramatically improve efficiency and productivity within their R&D organizations,” said David Pearson, newly appointed board member, IntelliChem. “IntelliChem is emerging as the clear market leader in this important space and I look forward to playing a key advisory role in IntelliChem’s future growth and market success.”
About Intelligent Electronic Laboratory Notebooks
Intelligent electronic lab notebooks (iELN) not only allow companies to replace paper laboratory notebooks with an electronic, searchable system, but they also provide collaborative decision-support tools to help scientists and engineers make better decisions. Only intelligent ELN systems can deliver the benefits that pharmaceutical and biotechnology companies require to dramatically improve productivity and efficiency in their global research and development organizations.
About IntelliChem
IntelliChem, Inc. is the leading provider of intelligent electronic lab notebooks (iELN) for discovery and development. Pharmaceutical, biotechnology, and fine chemicals companies can improve productivity, enable collaboration, improve quality, and ensure regulatory compliance through the adoption of IntelliChem solutions. IntelliChem Discovery & Development Solutions (IDS) were developed and validated through partnership with six major pharmaceutical companies, including Merck & Co., Pfizer, and Bristol-Myers Squibb. IntelliChem is a privately held company with headquarters and development facilities located in Bend, Oregon. For more information, visit www.intellichem.com .
